Drug information for VIRACEPT

Form Dosage Status Therapeutic Equivalence Active Ingred Ref. Sponsor Document
POWDER; ORAL EQ 50MG BASE/SCOOPFUL Prescription  (Reference Drug) NELFINAVIR MESYLATE Nelfinavir AGOURON 20778
2012-04-11 Letter
2012-04-09 Label
2012-02-27 Letter
2012-02-24 Label
2011-03-10 Label
2011-02-28 Letter
2010-05-03 Label
2010-05-03 Label
2010-04-28 Letter
2010-04-28 Letter
2008-11-26 Letter
2008-02-14 Label
2008-02-14 Letter
2007-12-03 Label
2007-08-06 Review
2007-08-06 Review
2007-08-06 Review
2007-08-06 Review
2007-01-08 Letter
2006-12-28 Label
2005-10-20 Letter
2005-09-30 Label
2004-06-07 Letter
2004-06-07 Label
2004-04-05 Label
2004-03-24 Letter
2003-08-29 Letter
2003-08-28 Label
2003-07-30 Letter
2003-04-04 Label
2002-02-05 Letter
2002-02-05 Letter
2001-04-11 Letter
1997-03-14 Review
TABLET; ORAL EQ 250MG BASE Prescription  (Reference Drug) NELFINAVIR MESYLATE Nelfinavir AGOURON 20779
2012-04-11 Letter
2012-04-09 Label
2012-02-27 Letter
2012-02-24 Label
2011-03-10 Label
2011-02-28 Letter
2010-05-03 Label
2010-05-03 Label
2010-04-28 Letter
2010-04-28 Letter
2008-11-26 Letter
2008-02-14 Letter
2008-02-14 Label
2007-12-03 Label
2007-08-06 Review
2007-08-06 Review
2007-08-06 Review
2007-08-06 Review
2007-08-06 Review
2007-08-06 Review
2007-01-08 Letter
2006-12-28 Label
2005-10-20 Letter
2005-09-30 Label
2004-06-07 Letter
2004-06-07 Label
2004-04-05 Label
2004-03-24 Letter
2003-08-29 Letter
2003-08-28 Label
2003-07-30 Letter
2003-04-30 Letter
2003-04-30 Letter
2003-04-30 Review
2003-04-30 Review
2003-04-04 Label
2002-02-05 Letter
2002-02-05 Letter
2001-04-11 Letter
1997-03-14 Review
TABLET; ORAL EQ 625MG BASE Prescription  (Reference Drug) NELFINAVIR MESYLATE Nelfinavir AGOURON 21503
2012-04-11 Letter
2012-04-09 Label
2012-02-27 Letter
2012-02-24 Label
2011-03-04 Label
2011-02-28 Letter
2010-05-03 Label
2010-05-03 Label
2010-04-28 Letter
2010-04-28 Letter
2008-11-26 Letter
2008-02-14 Label
2008-02-14 Letter
2007-08-06 Review
2007-08-06 Review
2007-08-02 Label
2007-01-08 Letter
2006-12-28 Label
2005-12-16 Review
2005-10-20 Letter
2005-09-30 Label
2004-06-07 Letter
2004-06-07 Label
2004-04-05 Label
2004-03-24 Letter
2003-08-29 Letter
2003-08-28 Label
2003-05-29 Letter
2003-05-06 Label

Drug Adverse Effects information for VIRACEPT

Role code Indications Reaction # Reports
SS ANTIRETROVIRAL THERAPY INTRA-UTERINE DEATH 5
SS ANTIRETROVIRAL THERAPY MATERNAL EXPOSURE DURING PREGNANCY 5
SS HIV INFECTION ABDOMINAL DISTENSION 7
SS HIV INFECTION ABDOMINAL HERNIA 7
SS HIV INFECTION CARDIAC MURMUR 7
SS HIV INFECTION CONGENITAL ANOMALY 7
SS HIV INFECTION CONGENITAL CYTOMEGALOVIRUS INFECTION 6
SS HIV INFECTION CONGENITAL INGUINAL HERNIA 3
SS HIV INFECTION CRYPTORCHISM 7
SS HIV INFECTION EXOMPHALOS 7
SS HIV INFECTION GASTROSCHISIS 7
SS HIV INFECTION MATERNAL DRUGS AFFECTING FOETUS 19
SS HIV INFECTION PREMATURE BABY 3
SS HIV INFECTION SICKLE CELL ANAEMIA 6
SS HIV INFECTION TRISOMY 21 3
SS HIV INFECTION UMBILICAL HERNIA 7
SS PRODUCT USED FOR UNKNOWN INDICATION ABDOMINAL DISTENSION 1
SS PRODUCT USED FOR UNKNOWN INDICATION ABDOMINAL HERNIA 1
SS PRODUCT USED FOR UNKNOWN INDICATION CARDIAC MURMUR 1
SS PRODUCT USED FOR UNKNOWN INDICATION CONGENITAL ANOMALY 1
SS PRODUCT USED FOR UNKNOWN INDICATION CRYPTORCHISM 1
SS PRODUCT USED FOR UNKNOWN INDICATION EXOMPHALOS 1
SS PRODUCT USED FOR UNKNOWN INDICATION GASTROSCHISIS 1
SS PRODUCT USED FOR UNKNOWN INDICATION MATERNAL DRUGS AFFECTING FOETUS 1
SS PRODUCT USED FOR UNKNOWN INDICATION UMBILICAL HERNIA 1
C ANTIBIOTIC PROPHYLAXIS CONVULSION 1
C EPILEPSY CONVULSION 1
C HIV INFECTION CONVULSION 3
C HIV INFECTION DEPRESSION 2
C HIV INFECTION ECZEMA 2
C HIV INFECTION HIDRADENITIS 1
C HIV INFECTION LIPODYSTROPHY ACQUIRED 2
C HIV INFECTION LIPOHYPERTROPHY 2
C HIV INFECTION OSTEONECROSIS 10
C HIV INFECTION PHARYNGOTONSILLITIS 2
C HIV INFECTION SINUSITIS 2
C HIV INFECTION SUICIDE ATTEMPT 2
C NEUROPATHY PERIPHERAL CONVULSION 1
Ads by Google